PETRI DISH PERSPECTIVES
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every THURSDAY!
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives
PETRI DISH PERSPECTIVES
February 2026: Biotech & Pharma NEWS Roundup
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026!
This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechNews #PharmaNews
© 2026 The Perspective Bureau LLC. All rights reserved.
Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, and a storyteller by choice.
Due to continued demand, I’m reporting monthly episodes for biotech and pharma news. Each monthly recap for news is released on the first day of every month and my goal is to deliver digestible pieces of news on pharma and biotech companies in under 15 mins.
Grab your coffee or tea cuz you’re in for a treat!
Novo Nordisk Battles Hims & Hers Over Compounded GLP-1s
https://www.cnbc.com/2026/02/09/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html
The Danish pharmaceutical giant Novo Nordisk, the leader in the weight-loss market with Wegovy and Ozempic, has filed a lawsuit against telehealth firm Hims & Hers to halt the sale of unauthorized "compounded" versions of their semaglutide drugs. While Hims & Hers has seen its stock surge by offering cheaper alternatives during supply shortages, Novo argues these oral formulations are unproven and potentially unsafe. The legal battle comes as Novo works to defend a multi-billion dollar franchise from regulatory loopholes.
Novo Nordisk and Vivtex Ink $2.1B Oral Obesity Deal
Continuing its dominance in the GLP-1 sector, Novo Nordisk partnered with Vivtex in a massive $2.1 billion deal focused on "oralizing" obesity drugs. Vivtex specializes in robotic high-throughput screening of the gastrointestinal tract to find ways to make large molecules absorbable through a pill. The goal is to move beyond injections, making weight-loss treatment as simple as taking a daily vitamin.
Lilly Acquires Orna Therapeutics to Master "Circular" RNA
Eli Lilly has moved to acquire Orna Therapeutics, a pioneer in "circular" RNA (oRNA) technology, for an undisclosed sum estimated to be in the mid-hundreds of millions plus milestones. Orna, which previously had a $150 million collaboration with Merck, focuses on creating more stable RNA that can be used for in-situ CAR-T cell therapies. This acquisition allows Lilly to bypass traditional cell manufacturing by "reprogramming" a patient's cells directly inside their body.
Lilly Pays CSL $100M for "Flunked" IL-6 Antibody
In a classic "salvage" play, Eli Lilly has paid $100 million upfront to CSL Behring for clazakizumab, an IL-6 antibody that recently failed a Phase 3 study for organ transplant rejection. While the drug missed its primary goal for CSL, Lilly believes its anti-inflammatory properties have significant potential in other areas, such as cardiovascular disease and metabolic health. CSL remains eligible for additional "success-based" milestones if Lilly successfully repurposes the asset.
Takeda and Iambic Ink $1.7 Billion AI Discovery Pact
Japan’s largest pharma company, Takeda, has entered into a strategic collaboration with San Diego-based Iambic Therapeutics in a deal worth over $1.7 billion in potential milestones. Iambic uses a physics-informed AI platform to design small molecules with better "drug-like" properties than traditional methods. The partnership will focus on accelerating the discovery of novel treatments for complex targets in inflammation and oncology.
Sanofi Reshuffles Leadership: Paul Hudson Out, Belén Garijo In
In a surprising move, the French giant Sanofi ousted CEO Paul Hudson following what investors described as a "bumpy ride" marked by R&D setbacks and a controversial strategy shift away from consumer health. The company has enlisted former Merck KGaA CEO Belén Garijo to take the helm, signaling a desire for more stable, science-focused leadership. Garijo, a veteran of the German pharmaceutical sector, is expected to prioritize Sanofi’s immunology and vaccine pipelines.
FDA Approves Dual-Action Leukemia Combo from AstraZeneca and AbbVie
The FDA has approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This "chemo-free" regimen marks a significant shift in the standard of care, offering a more targeted and less toxic approach for elderly patients. The approval is expected to drive significant revenue growth for AstraZeneca and AbbVie, the respective manufacturers of the two drugs.
AstraZeneca and Leon Wang Face Indictment in China
The Chinese government has formally indicted AstraZeneca and its former high-ranking executive Leon Wang on charges related to illegal data collection and trade violations. The case centers on allegations that the company improperly accessed patient data to drive sales of oncology drugs like Tagrisso. This legal turmoil has sent shockwaves through the industry, as AstraZeneca is one of the largest and most established foreign pharmaceutical players in the Chinese market.
FDA Clears First-of-Its-Kind "Sonic" Device for Pancreatic Cancer
The FDA has approved a breakthrough medical device from HistoSonics that uses histotripsy (focused ultrasound) to mechanically destroy pancreatic tumors. Unlike traditional radiation, this "first-of-its-kind" technology uses sound waves to liquify cancer cells without damaging surrounding healthy tissue. This approval offers a new non-invasive option for patients with one of the most difficult-to-treat forms of cancer.
Novartis Bets $1.7B on Unnatural Products’ Macrocycles
Novartis has entered a massive $1.7 billion partnership with Unnatural Products (UNP), a California-based biotech that uses AI to design "macrocyclic" drugs. Macrocycles are large molecules that can hit targets traditional small molecules can’t reach, but they are notoriously difficult to design. This deal allows Novartis to leverage UNP’s platform to go after "undruggable" oncology and immunology targets.
Sanofi Backs Altesa’s $75M Push for Rhinovirus Cure
Altesa BioPharma secured a $75 million Series B round, led by Sanofi’s venture arm, to bankroll Phase 2b trials for its lead antiviral, ALT-2023. The drug is being developed specifically to treat severe rhinovirus (the common cold) in high-risk patients, such as those with asthma or COPD. If successful, Altesa could provide the first pharmacological solution for a virus that currently has no approved treatment.
Gilead to Acquire Arcellx to Dominate the CAR-T Space
Gilead Sciences, through its subsidiary Kite Pharma, has announced the acquisition of Arcellx for an undisclosed sum to fully secure the future of Anito-cel, a next-gen CAR-T therapy. Arcellx’s technology uses a smaller "binding domain" that may make the therapy safer and more effective than current options for multiple myeloma. This move solidifies Gilead’s position as the dominant player in the increasingly crowded cell therapy market.
Charles River Divests Discovery Units to Pivot Toward High-Growth
Charles River Laboratories, one of the world’s largest contract research organizations (CROs), has sold off several of its legacy manufacturing and early-stage discovery businesses. The company is fulfilling a "promised pivot" to focus exclusively on high-margin, high-growth sectors like cell and gene therapy and AI-driven toxicology. This restructuring is intended to streamline the business and improve profitability in a more competitive outsourcing landscape.
Eikon Therapeutics Hits the Public Markets with $381M Debut
Eikon Therapeutics, a California-based biotech pioneer using super-resolution microscopy to track live-cell protein dynamics, completed an upsized $381 million Nasdaq listing. This marks the largest biotech IPO since early 2024, signaling a renewed investor appetite for "platform" companies with high-tech discovery engines. The funds will be used to advance their lead oncology and neurodegeneration programs into mid-stage clinical trials.
Agomab and SpyGlass Raise $350M in Combined IPOs
https://www.fiercebiotech.com/biotech/agomab-spyglass-head-nasdaq-ipos-totalling-350m
In a double-win for the Nasdaq, Belgian-based Agomab Therapeutics and California's SpyGlass Pharma successfully went public with offerings totaling $350 million. Agomab is focused on regenerative medicine and fibro-inflammatory diseases, while SpyGlass specializes in long-acting drug delivery systems for chronic eye conditions like glaucoma. These listings further cement the trend of specialized, mid-stage biotechs successfully navigating the 2026 IPO window.
QuantX Biosciences Secures $85M for Precision Diagnostics
QuantX Biosciences, a specialist in AI-driven protein quantification and molecular diagnostics, closed an oversubscribed $85 million Series B financing round. The company provides ultra-sensitive testing platforms used by major labs to detect early-stage Alzheimer’s and rare cancers. The new capital will fund the commercial rollout of their "next-gen" diagnostic kits across the U.S. and European markets.
Merck Splits Oncology Unit Ahead of Keytruda "Patent Cliff"
With the 2028 patent expiration of its superstar drug Keytruda looming, Merck has split its oncology division into a standalone business unit. This structural move is designed to maximize the "tail-end" revenue of Keytruda while aggressively accelerating the development of its "Keytruda 2.0" pipeline, which includes subcutaneous versions and new combinations. The split allows for more focused capital allocation during one of the most critical transitions in the company's history.
With that, that is a wrap for February 2026 news.
This has been Petri Dish Perspectives. I’m Manead. I’ll be back next month with a recap on March. Thanks for listening. Goodbye!
© 2026 Petri Dish Perspectives LLC. All rights reserved.
